rs11204971 — FLG FLG locus regulatory variant

FLG Locus — Skin Barrier Regulation and the Atopic March

Filaggrin is the key structural protein of the outermost skin layer. Encoded by the FLG gene at chromosome 1q21.3, it aggregates keratin filaments into the waterproof matrix of the stratum corneum¹¹ aggregates keratin filaments into the waterproof matrix of the stratum corneum
Profilaggrin is cleaved into 10–12 filaggrin monomers during terminal epidermal differentiation; the monomers compact keratin and their breakdown products form NMF — the mixture of amino acids, urocanic acid, and urea that keeps skin hydrated and acidic. When filaggrin levels are reduced — through coding mutations that eliminate protein entirely, or through regulatory variants that lower expression — transepidermal water loss rises, skin pH increases, and gaps form between surface skin cells that allow environmental allergens to penetrate and trigger immune sensitization.

rs11204971 is a regulatory tag SNP in the FLG locus identified in genome-wide association studies of atopic dermatitis in Chinese Han populations. Unlike the classic loss-of-function coding mutations (R501X, 2282del4, S3247X) that are common in Europeans, this variant tags a haplotype associated with reduced FLG expression — it marks a regulatory change in how much filaggrin the skin produces rather than making a truncated or absent protein. The G allele shows a striking population distribution: approximately 57% frequency in East Asians compared to 14% in Europeans and 4% in Africans, reflecting the distinct spectrum of FLG variation across ancestry groups.

The Mechanism

The FLG locus at 1q21.3 is regulated by a complex of enhancers and intronic elements that control filaggrin expression during terminal epidermal differentiation. Regulatory SNPs in this region can alter transcription factor binding, splicing efficiency, or enhancer activity without changing the protein sequence. Reduced filaggrin from regulatory variants produces the same downstream consequences as loss-of-function coding mutations — insufficient natural moisturizing factor (NMF)²² natural moisturizing factor (NMF)
a hygroscopic mixture of amino acids, urocanic acid, pyrrolidone carboxylic acid, urea, and ions derived from filaggrin breakdown that retains water in the stratum corneum and maintains the acidic skin pH that suppresses pathogens, elevated transepidermal water loss, and a permissive state for percutaneous allergen entry. The magnitude of effect for regulatory variants is typically smaller than for null coding mutations, but the mechanism is identical.

The Evidence

The FLG 1q21.3 locus was confirmed in a large Chinese Han GWAS³³ large Chinese Han GWAS
Sun et al. 2011: 1,012 AD cases and 1,362 controls in discovery, 3,624 cases and 12,197 controls in replication, plus 1,806 German cases; tag SNP rs3126085 showed OR=0.82 (P=5.90×10⁻¹²) for the protective allele and across European populations. rs11204971 was used alongside rs3126085 as a secondary tag SNP for this locus in follow-up Chinese Han studies⁴⁴ follow-up Chinese Han studies
Tang et al. 2012: examined rs11204971 and rs3126085 alongside three other AD susceptibility SNPs, finding FLG association with AD but not asthma in 463 asthma cases and 985 controls — suggesting distinct genetic architectures for the two atopic conditions.

The broader FLG literature — built primarily on coding loss-of-function mutations but applicable to regulatory variants through the same mechanism — shows robust effects. A meta-analysis of 24 studies⁵⁵ meta-analysis of 24 studies
Van den Oord & Sheikh 2009: 5,791 eczema cases, 26,454 controls; asthma analysis in 17 studies found FLG haploinsufficiency associated with eczema at OR 3.12 (95% CI 2.57–3.79) and the combined eczema-plus-asthma phenotype at OR 3.29. Importantly, the asthma association was only present in the context of existing eczema — FLG variants do not independently predispose to asthma absent skin barrier disruption — supporting a percutaneous sensitization model where allergens breach the defective skin barrier, trigger IgE-mediated sensitization, and drive the downstream atopic march.

Practical Actions

The central intervention for reduced filaggrin expression is external barrier support. Ceramide-dominant emollients⁶⁶ Ceramide-dominant emollients
formulations containing ceramides, cholesterol, and free fatty acids in approximately a 3:1:1 molar ratio most closely replicate the physiologic lipid composition of the stratum corneum compensate for reduced NMF production. A randomized controlled trial⁷⁷ randomized controlled trial
Simpson et al. 2014: 124 high-risk neonates randomized to daily full-body emollient vs no treatment from birth found daily emollient application from birth cut the cumulative incidence of atopic dermatitis by 50% (RR 0.50; 95% CI 0.28–0.90).

Barrier-disrupting personal care ingredients — sodium lauryl sulfate, fragrance, methylisothiazolinone — penetrate compromised skin more readily and cause disproportionate damage when filaggrin levels are suboptimal. Eliminating these from daily products is a high-leverage, low-risk intervention for G allele carriers.

For infants of G allele carriers, particularly those of East Asian ancestry where the G allele is common and AD prevalence is high, early introduction of common food allergens and emollient prophylaxis from birth represent the two most evidence-supported prevention strategies for interrupting the atopic march.

Interactions

rs11204971 tags the same FLG locus haplotype as rs3126085 and co-listed rs12123821. These variants are in linkage disequilibrium and reflect the same underlying biology — reduced filaggrin expression through regulatory mechanisms at 1q21.3. Carriers of classical FLG null coding mutations (rs61816761 / R501X, rs558269137 / 2282del4) have a more severe baseline because those mutations eliminate protein from the affected allele entirely, compared to the partial expression reduction from regulatory variants. When a person carries both a regulatory variant (rs11204971 G) and a coding null mutation on the other chromosome, the combined effect approaches that of compound heterozygosity for two null alleles.

rs11204971 shows no independent association with asthma in the absence of atopic dermatitis, which is consistent with the percutaneous sensitization model: FLG-driven systemic Th2 skewing requires active barrier disruption and allergen penetration through eczematous skin.